The work of the Health Technology and Services Research group (HTSR) revolves around how medical technology can make the clinical and economic aspects of healthcare more efficient. A new method is considered at an early stage – ideally the development stage – so as to reveal whether the new technology should be introduced or discontinued. The issue when introducing medical technology is what effect it will have on the quality and funding of medical care.
The work of the Health Economics of Personalized and Translational Medicine chair in the Health Technology and Services Research department (HTSR) revolves around the clinical outcomes and health economics of medical technologies, in particular of personalized medicine technologies. The research focuses at the evidence synthesis and decision analytic modeling of companion diagnostics and image markers to guide clinical decisions. The value of new medical technologies for the healthcare system is determined from a broad perspective, including the use of preference elicitation methods to determine preferences for health outcomes from a wide range of patients and physicians. Translational Health Economics is the new field of research, where value of new medical technologies is determined at an early stage – ideally the development stage – so as to reveal whether the new technology should be introduced or discontinued. Examples of recent projects in MIRA are the use of liquid biopsies and biomarkers may guide therapy decisions, where the research group develops personalized decision models employing patient-level simulations and collaborates with computer science on machine learning methods to explore large datasets.
For more information about Health Technology and Services Research and the HTA and Personalized Medicine chair, visit the homepage of this research group.